Diginex Limited’s DGNX share price has surged by 11.20%, which has investors questioning if this is right time to sell.

In the assessment of 12-month price targets, analysts unveil insights for AVITA Medical, presenting an average target of $22.0, a high estimate of $25.00, and a low estimate of $14.00. This current ...

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New York--(Newsfile Corp. - ...

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

Bilen et al. perform a phase 2 single-arm clinical trial of neoadjuvant cabozantinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma, assess efficacy and find ...

This Perspective outlines evidence on existing platform trials in mental health and discusses key challenges and strategies to overcome barriers in order to maximize the potential of platform trials.

Amazon’s Good Omens Summons Michael Sheen and David Tennant to the ApocalypseThe studio plans to adapt Neil Gaiman and Terry Pratchett’s novel into an hour-long limited comedy series.

Opposition figures accused of conspiring against the state Accused say charges are fabricated by authoritarian leader Trial postponed to April 11 TUNIS, March 4 (Reuters) - The trial of prominent ...

Once again, you're getting everything on Disney Plus and Star for that price. Sadly, you can't get a 7-day Disney Plus free trial anymore. Or any kind of free trial, actually; it was removed a few ...

Thousands of men are to be checked for prostate cancer in one of the first large-scale European trials of smart screening. The pilot study, starting next week in Ireland, will combine a blood test ...

Robert E. Crimo III changed his original not-guilty plea to guilty moments before his trial was set to begin with opening statements Monday, March 3. During the hearing, Judge Victoria Rossetti ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...